Real-word Study for Fondaparinux

A multicenter, prospective, pragmatic clinical trial for fondaparinux in the treatment of Chinese patients with non-ST-segment elevation acute coronary syndrome

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025366

Enrollment

Unknown

Registered

2019-08-25

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSTE-ACS

Interventions

Fondaparinux:anticoagulant therapy

LMWH:anticoagulant therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. aged>18 years; 2. NSTE-ACS patients; 3. The subject or legal representative has been informed of the nature of the study, understands the protocol, is able to ensure compliance, and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. STEMI patients; 2. NSTE-ACS patients undergoing emergency invasive therapy; 3. Contraindications or allergies to Fondaparinux, UFH, LMWH, aspirin, clopidogrel or tegrilol; 4. Participating in other drug/device studies or during follow-up to another drug/device study; 5. Patients may not adhere to the study protocol (including the follow-up period), such as mental disorders, alcohol or drug abuse.

Design outcomes

Primary

Measure	Time frame
Death;Major bleeding;MI;Stroke;	—

Countries

China

Contacts

Public ContactChen Yundai

China PLA General Hospital

cyundai@vip.163.com+86 010-55499009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026